Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28645405 | 0.98 | ALDH1A1 (0.56) | ALDH1A1TDP1GAACYP2D6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27501008 | 0.98 | ALDH1A1 (0.56) | ALDH1A1TDP1GAACYP2D6SMN1; SMN2 | |
| SCHEMBL65441 | 0.98 | ALDH1A1 (0.50) | ALDH1A1TDP1GAACYP2D6SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4391137 | 0.95 | ALDH1A1 (0.53) | ALDH1A1TDP1GAACYP2D6SMN1; SMN2 | |
| SCHEMBL28738942 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL28912856 | 0.91 | ALDH1A1 (0.49) | ALDH1A1TDP1GAACYP2D6SMN1; SMN2 | |
| SCHEMBL70778 | 0.88 | TSHR (0.46) | ALDH1A1TDP1GAASMN1; SMN2KDM4E | |
| SCHEMBL12379861 | 0.88 | TSHR (0.46) | ALDH1A1TDP1GAASMN1; SMN2KDM4E | |
| SCHEMBL1133592 | 0.88 | — | — | |
| SCHEMBL19379914 | 0.85 | ALDH1A1 (0.49) | ALDH1A1TDP1GAACYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216299-A | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer | MERCK PATENT GMBH | 2011-10-12 | — | — | CN | claimed |
| EP-4660703-A2 | METAL-CONTAINING FILM PATTERNING PROCESS | Shin-Etsu Chemical Co., Ltd. (JP) | 2025-12-10 | — | — | EP | disclosed |
| US-20250372377-A1 | METAL-CONTAINING FILM PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-3099304-B1 | CHROMAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF GLAUCOMA | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12032287-B2 | Resist material and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11994798-B2 | Resist material and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-05-28 | — | — | US | disclosed |
| EP-3686185-B1 | FLUORENE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING HCV-RELATED DISEASE | SEOUL NAT UNIV R&DB FOUNDATION (KR) | 2023-12-13 | — | — | EP | disclosed |
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | ODDITY LABS, LLC | 2023-08-03 | — | — | US | disclosed |
| US-11230557-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-1041203-C | Process for producing pyrazolopyridine compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | CN | disclosed |
| CN-1201033-A | Solid chemical compound, preparation method therefor and use in medicine | JOHNSON MATTHEY CO LTD (GB) | 1998-12-09 | — | — | CN | disclosed |
| CN-1183770-A | Piperazine derivatives, medicaments containing these compounds, their use and processes for their preparation | THOMAE GMBH DR K (DE) | 1998-06-03 | — | — | CN | disclosed |
| EP-0800516-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5661107-A | ACYLUREA ACTIVE IN SMALL DOSAGE, HIGH SELECTIVITY | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-08-26 | — | — | US | disclosed |
| CN-1156995-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-08-13 | — | — | CN | disclosed |
| WO-1997025323-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
| US-5576431-A | Method for production of perfluoro-cyclic imine | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY, MINISTRY OF INTERNATIONAL TRADE & INDUSTRY (JP) | 1996-11-19 | — | — | US | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| CN-1085902-A | Heterogeneous ring compound | DEGUSSA (DE) | 1994-04-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230557-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | ALDH1A1 4766/4885TDP1 3445/4885GAA 2390/4885 |
| US-20230240960-A1 | COMPOSITIONS, FORMULATIONS, AND METHODS FOR SKIN TREATMENT | CUTA, COL14A1, DSG1 | ALDH1A1 3302/4885TDP1 1034/4885GAA 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.